Acción·LSE·£
Editas Medicine, Inc. is a clinical-stage company dedicated to developing innovative genomic medicines that address a range of serious diseases. The company utilizes its proprietary gene editing platform, which is founded on CRISPR technology. Its robust pipeline includes EDIT-101, currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic condition causing childhood blindness. Additionally, Editas is developing EDIT-102 for Usher Syndrome 2A, a form of retinitis pigmentosa also linked to hearing loss, and for autosomal dominant retinitis pigmentosa. Another key therapeutic candidate is EDIT-301, aimed at treating sickle cell disease and transfusion-dependent beta-thalassemia. Beyond these programs, the company is advancing gene-edited Natural Killer cell medicines for solid tumors, as well as alpha-beta and gamma delta T cell therapies for various cancers. An early-stage discovery program is also underway for a neurological disease. Editas Medicine maintains strategic collaborations, including a research partnership with Juno Therapeutics, Inc. for engineered T cells in cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover and commercialize gene editing therapies for ocular disorders; and research collaborations with Asklepios BioPharmaceutical, Inc. (AskBio) for a neurological disease treatment. Incorporated in 2013, and formerly known as Gengine, Inc. until its name change in November of that year, Editas Medicine, Inc. is based in Cambridge, Massachusetts.
Ve el precio de 0IFK.L en vivo en tu pantalla física de escritorio. Configura alertas con las apps iOS y Android.
